New vaccine combo aims to keep high-risk neuroblastoma at bay
NCT ID NCT04936529
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This study tests whether a bivalent vaccine, combined with beta-glucan and GM-CSF, can help prevent high-risk neuroblastoma from coming back in children who are currently in complete remission. The treatment aims to strengthen the immune system to recognize and attack any remaining cancer cells. About 286 participants will be enrolled to see if adding GM-CSF improves the immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.